While there is a rich literature on general guideline attitudes and adherence, the differences in likelihood and reasoning for selecting between clinical management strategies that have different levels of guideline support has been sparingly investigated.
Adjusting for adherence, the differences among these clinical trials have been attributed to the increased accumulation of active drug in colorectal versus vaginal tissue.
For example, auxiliary analyses indicate that if the baseline adherence rate were only 32%%, a third of the population did not accurately report their adherence barrier, and if a third developed a new adherence barrier, the difference in adherence with RL versus standard tailoring would be more than twice that presented here.
Once-daily compared with twice-daily antiretroviral therapy regimens increased adherence; however, the difference was modest and not associated with a difference in virological suppression.
The average total costs during the follow up period were lower in members demonstrating low adherence as compared to those with high adherence, although the differences were not significant (M = $15,528, SD = $37,713 versus (M = $21,033, SD = $13,136, F = 3.35, p = 0.068).
For the studies in which the SD of the adherence outcome was reported together with its mean, we conducted a more formal estimation of the adherence-enhancing effect, measured by the difference between the adherence outcome of each intervention and the control group of each study (and aggregated 95%% confidence interval) resulting from the different intervention types identified.
Although adherence to the polypill should be similar, adherence to four monocomponents may be lower than adherence to three, so our model may have overestimated the difference in adherence in the two groups.
As secondary non-adherence refers to the amount of prescribed drugs and not to the patients' filled prescriptions, the drug cost related to non-adherence is defined as the difference in cost between actual, filled prescriptions (primary adherence) and a calculated estimation of the total cost of the amount of drugs taken as prescribed (secondary adherence).
Participants' dietary adherence was assessed as the difference between their respective assigned diet's recommended macronutrient goals and their self-reported intake.
Changes in utilization and adherence were calculated as the difference between year 2 (follow-up) and year 1 (baseline) values.
